Group 1 - The company held its ninth meeting of the sixth board of directors on August 13, 2025, with all nine directors present, complying with legal and regulatory requirements [2][3]. - The board approved a resolution to sign a settlement agreement with Jianyuan Trust Co., Ltd. regarding a financial product dispute, with unanimous support from all directors [2][3]. Group 2 - The settlement agreement was reached on August 13, 2025, where Jianyuan Trust paid the company a settlement amount of 56,994,275.53 yuan, which is 50% of the remaining amount after deducting previously paid principal and interest from the original investment of 170 million yuan [3][11]. - The company will submit a request to withdraw the lawsuit to the Shanghai Financial Court, and the transfer of 62,862,549.50 trust beneficiary rights to Jianyuan Trust will occur, while the company retains the remaining rights [3][11]. Group 3 - The total amount involved in the settled case was 177.8694 million yuan, with the principal amount being 170 million yuan [9][10]. - The settlement is expected to impact the company's profit by approximately 48.4451 million yuan, which will be included in the 2025 annual report [9][13].
常州千红生化制药股份有限公司 第六届董事会第九次会议决议公告